EVAXION A/S(NASDAQ:EVAX) stock News

EVAX Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Evaxion

Evaxion to present at several conferences during the second half of 2025

a month ago - By: Evaxion

Evaxion announces business update and second quarter 2025 financial results

a month ago - By: Benzinga - Mentions: BTCM DE TIC DFLI ...

Earnings Scheduled For August 14, 2025

a month ago - By: Benzinga

Insights Ahead: Evaxion Biotech's Quarterly Earnings

a month ago - By: Evaxion

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

a month ago - By: Evaxion

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

2 months ago - By: Evaxion

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

2 months ago - By: Evaxion

Evaxion finalizes agreement with EIB to convert debt into equity

2 months ago - By: Evaxion Biotech

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

3 months ago - By: Evaxion Biotech

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

3 months ago - By: Evaxion Biotech

Evaxion receives grant funding to design new polio vaccine

4 months ago - By: Evaxion Biotech

Evaxion announces business update and first quarter 2025 financial results

4 months ago - By: Evaxion Biotech

Evaxion announces business update and first quarter 2025 financial results

4 months ago - By: Evaxion Biotech

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

4 months ago - By: Evaxion Biotech

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

4 months ago - By: ACCESS Newswire - Mentions: ULY HTCR DGXX LWLG ...

Sidoti Events, LLC's Virtual May Micro-Cap Conference

5 months ago - By: Evaxion Biotech

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

5 months ago - By: Evaxion Biotech

Evaxion to present at World Vaccine Congress

6 months ago - By: Evaxion Biotech

Evaxion announces business update and full year 2024 financial results

6 months ago - By: Evaxion Biotech

Evaxion announces business update and full year 2024 financial results

6 months ago - By: Evaxion Biotech

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

6 months ago - By: Evaxion Biotech

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

7 months ago - By: Evaxion Biotech

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

7 months ago - By: Evaxion Biotech

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

7 months ago - By: Evaxion Biotech

EVAXION A/S (EVAX) Stock News

EVAX Latest News, Press Relases and Analysis

Evaxion to present at several conferences during the second half of 2025

Evaxion announces business update and second quarter 2025 financial results

Earnings Scheduled For August 14, 2025

Insights Ahead: Evaxion Biotech's Quarterly Earnings

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Evaxion finalizes agreement with EIB to convert debt into equity

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Evaxion receives grant funding to design new polio vaccine

Evaxion announces business update and first quarter 2025 financial results

Evaxion announces business update and first quarter 2025 financial results

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Sidoti Events, LLC's Virtual May Micro-Cap Conference

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Evaxion to present at World Vaccine Congress

Evaxion announces business update and full year 2024 financial results

Evaxion announces business update and full year 2024 financial results

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination

Evaxion announces closing of $10.8 million public offering